• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CEO and President Burnett Joseph sold $282,373 worth of shares (21,247 units at $13.29) (SEC Form 4)

    6/11/25 9:50:33 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care
    Get the next $CLPT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BURNETT JOSEPH

    (Last) (First) (Middle)
    C/O CLEARPOINT NEURO, INC.
    120 S. SIERRA AVE., SUITE 100

    (Street)
    SOLANA BEACH CA 92075

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ClearPoint Neuro, Inc. [ CLPT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    CEO and President
    3. Date of Earliest Transaction (Month/Day/Year)
    06/09/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/09/2025 S(1) 21,247 D $13.29(2) 243,522 I See Footnote(3)
    Common Stock 25,363 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This sale of shares is incident to the net share settlement of 21,247 shares which vested on March 6, 2025 under a restricted stock unit granted to the reporting person on March 6, 2023.
    2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $13.20 to $13.51. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
    3. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.
    /s/ Danilo D'Alessandro, by Power of Attorney for Joseph M. Burnett 06/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CLPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLPT

    DatePrice TargetRatingAnalyst
    7/25/2024$10.00Buy
    B. Riley Securities
    10/24/2023$8.00Buy
    Stifel
    2/16/2023$14.00Buy
    B. Riley Securities
    4/5/2022$15.00Buy
    B. Riley Securities
    More analyst ratings

    $CLPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

      Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United StatesSOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This signifies th

      11/13/24 1:20:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Reports Third Quarter 2024 Results

      Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024.Third Quarter HighlightsReported quarterly revenue of $8.1 million, a 41% year-over-year increase;Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of $2.9 million, a 53% year-over-year increase;Overall product revenue, inc

      11/7/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

      President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast TodaySOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguards of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found HERE.Healthcare Conferences with Participation of ClearPoint Neuro Management Include:UBS Global Healthcare Conference in

      10/31/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

      For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

      11/14/24 8:50:18 AM ET
      $CLPT
      $PTCT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CLPT
    Financials

    Live finance-specific insights

    See more
    • ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

      SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 third quarter on Thursday, November 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or a

      10/17/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

      SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 second quarter on Wednesday, August 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or

      7/17/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024

      SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 first quarter on Tuesday, May 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 first quarter on Tuesday, May 7th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201

      4/23/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CLPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/12/24 2:35:26 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/8/24 4:33:36 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/4/24 11:28:38 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

      SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to have Mazin join our team and bring his valuable and relevant skill set into our organization," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Our pharma and device partners in many ways view ClearP

      9/20/22 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs

      SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mary McNamara-Cullinane has joined the Company as Vice President of Regulatory Affairs. Ms. McNamara-Cullinane will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to welcome Mary to our team as we fully expect her leadership and experience in Regulatory Affairs will contribute immediately to our partners and to patients globally," commented Joe Burnett, Presiden

      8/8/22 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors

      SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company's Board of Directors effective immediately. Ms. Fallon will also become a member of the Company's Audit Committee. Ms. Fallon is the Executive Vice President, HR/Legal, General Counsel and Secretary of Axcelis Technologies, Inc. (NASDAQ:ACLS), a provider of equipment and service solutions for the semiconductor manufacturing industry, with locations in eight countries. Ms. Fallon has held her current position sin

      7/15/21 4:30:00 PM ET
      $CLPT
      $ACLS
      Medical/Dental Instruments
      Health Care
      Industrial Machinery/Components
      Technology

    $CLPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Richards Timothy T. sold $132,800 worth of shares (10,000 units at $13.28), decreasing direct ownership by 11% to 77,381 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      6/12/25 7:26:56 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer D'Alessandro Danilo covered exercise/tax liability with 4,754 shares, decreasing direct ownership by 7% to 65,992 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      6/12/25 7:17:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Business Officer Stigall L. Jeremy covered exercise/tax liability with 3,561 shares, decreasing direct ownership by 5% to 70,747 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      6/12/25 7:14:45 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    SEC Filings

    See more
    • SEC Form 144 filed by ClearPoint Neuro Inc.

      144 - ClearPoint Neuro, Inc. (0001285550) (Subject)

      6/3/25 4:13:31 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      5/23/25 4:30:10 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      5/19/25 4:30:08 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

      B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $10.00

      7/25/24 8:27:37 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on ClearPoint Neuro with a new price target

      Stifel initiated coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $8.00

      10/24/23 6:18:03 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

      B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $14.00

      2/16/23 7:44:43 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care